Atlas Venture Life Science Advisors, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001917529

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 7 positions · Total reported value $881.29M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 55.6% · 2 new · 3 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -11.8% · vs SPY -13.9% · Prev Value $881.29M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +13.7% · vs SPY +11.5% · Latest Value $631.19M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Atlas Venture Life Science Advisors, LLC disclosed 7 equity positions with a combined reported value of $881.29M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were KYMR ($326.53M), DYN ($151.03M), SION ($131.78M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Atlas Venture Life Science Advisors, LLC opened 2 new positions, trimmed 3 and fully exited 0, a turnover rate of 55.6% of positions. The portfolio's overlap with the prior quarter was 86% of names.

The largest new positions opened in Q2 2026 were KLRA ($113.92M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • KLRA KAILERA THERAPEUTICS INC · $113.92M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Atlas Venture Life Science Advisors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Atlas Venture Life Science Advisors, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 7 US equity positions with a combined value of $881.29M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 7 positions · $881.29M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: KYMR (KYMERA THERAPEUTICS INC) at 37.1%
  • Average position size: $125.90M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 1 added, 3 reduced
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Atlas Venture Life Science Advisors appears to be maintaining a cautious stance, with a slight reduction in positions across the board. The fund's adjustments suggest a preference for stability and a focus on companies with proven track records or strong potential, rather than taking on significant risk through aggressive growth investments. 2. Key Moves: - Reduced Positions: KYMERA THERAPEUTICS (KYMR) and DYNE THERAPEUTICS (DYN) saw significant reductions in shareholdings (-37.8% and -25.5% QoQ, respectively), indicating a shift away from these companies. - Added Positions: KAILERA THERAPEUTICS (KLRA) was added to the portfolio, signifying a new bet on this company's potential. - Increased Positions: Q32 Bio (QTTB) saw a 29.9% increase in shareholdings, reflecting a belief in its growth prospects. 3. Portfolio Structure: - Passive vs. Active: The portfolio seems to be leaning towards a more active management approach, with a focus on specific positions and strategic adjustments rather than a passive, index-following strategy. - Sector Bias: The fund has a strong bias towards the healthcare sector, reflecting its focus on life sciences. - Risk Appetite: The risk appetite appears moderate, with a preference for companies with established positions or strong potential, rather than high-risk, high-reward investments. 4. Per-Holding One-Liner: - KYMERA THERAPEUTICS (KYMR): A biotechnology company focused on developing therapies for immune disorders. - DYNE THERAPEUTICS (DYN): A biopharmaceutical company specializing in the development of treatments for blood disorders. - SIONNA THERAPEUTICS (SION): A biotechnology company focused on the development of therapies for ophthalmic diseases. - KAILERA THERAPEUTICS (KLRA): A biotechnology company focused on the development of therapies for inflammatory and autoimmune diseases. - DISC MEDICINE (IRON): A biotechnology company focused on the development of treatments for neurological disorders. - Q32 Bio (QTTB): A biotechnology company focused on the development of therapies for cardiovascular diseases. - KORRO BIO (KRRO): A biotechnology company focused on the development of therapies for infectious diseases. 5. One-Sentence Style Summary: Atlas Venture Life Science Advisors maintained a conservative approach in Q2 2026, focusing on established and promising biotech companies within the healthcare sector, while selectively adding new positions and reducing exposure to less promising ones.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.85M $326.53M 37.05%
37.05%
Reduce
2 6.80M $151.03M 17.14%
17.14%
Reduce
3 3.00M $131.78M 14.95%
14.95%
Hold
4 5.17M $113.92M 12.93%
12.93%
New
5 1.51M $110.72M 12.56%
12.56%
Hold
6 2.72M $34.62M 3.93%
3.93%
Add
7 962.88K $12.69M 1.44%
1.44%
Reduce

FAQ

What did Atlas Venture Life Science Advisors, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Atlas Venture Life Science Advisors, LLC reported 7 equity positions worth $881.29M in aggregate; its largest disclosed positions were KYMR ($326.53M), DYN ($151.03M), SION ($131.78M).

How large is Atlas Venture Life Science Advisors, LLC's portfolio?

Atlas Venture Life Science Advisors, LLC reported $881.29M of long equity holdings across 7 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Atlas Venture Life Science Advisors, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/atlas-venture-life-science-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →